Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and tolerability of long-term treatment with omalizumab
plus current asthma therapy in patients who participated in and successfully completed the
treatment period of study CIGE025IA04E1. Patients who participated in CIGE025IA04E1 were
perceived by both the patient and the investigator to have benefited from receiving treatment
with omalizumab plus current asthma therapy according to best medical practice